{"organizations": [], "uuid": "a3ef6438074598e48df8f796c91af015ff01d080", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180215.html", "section_title": "Archive News &amp; Video for Thursday, 15 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-celgene-says-otezla-phase-ii-data/brief-celgene-says-otezla-phase-ii-data-showed-clinically-meaningful-improvements-in-active-ulcerative-colitis-patients-idUSFWN1Q5126", "country": "US", "domain_rank": 408, "title": "BRIEF-Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.254, "site_type": "news", "published": "2018-02-15T23:13:00.000+02:00", "replies_count": 0, "uuid": "a3ef6438074598e48df8f796c91af015ff01d080"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-celgene-says-otezla-phase-ii-data/brief-celgene-says-otezla-phase-ii-data-showed-clinically-meaningful-improvements-in-active-ulcerative-colitis-patients-idUSFWN1Q5126", "ord_in_thread": 0, "title": "BRIEF-Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "celgene corp", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 15 (Reuters) - Celgene Corp:\n* OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS\n* CELGENE CORP - ‍PHASE III PROGRAM WITH OTEZLA (APREMILAST) IN ULCERATIVE COLITIS EXPECTED TO BEGIN IN 2018​\n* CELGENE CORP - ‍PRIMARY ENDPOINT OF STUDY WAS TOTAL MAYO SCORE CLINICAL REMISSION AT WEEK 12 FOR 40 MG BID ARM​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T23:13:00.000+02:00", "crawled": "2018-02-16T16:53:16.006+02:00", "highlightTitle": ""}